SE9604581D0 - An agent against cancer and virus infections - Google Patents

An agent against cancer and virus infections

Info

Publication number
SE9604581D0
SE9604581D0 SE9604581A SE9604581A SE9604581D0 SE 9604581 D0 SE9604581 D0 SE 9604581D0 SE 9604581 A SE9604581 A SE 9604581A SE 9604581 A SE9604581 A SE 9604581A SE 9604581 D0 SE9604581 D0 SE 9604581D0
Authority
SE
Sweden
Prior art keywords
against cancer
virus infections
agent against
antigens
impaired
Prior art date
Application number
SE9604581A
Other languages
English (en)
Swedish (sv)
Inventor
Elisabeth Wolpert
Klas Kaerre
Max Pettersson
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE9604581A priority Critical patent/SE9604581D0/xx
Publication of SE9604581D0 publication Critical patent/SE9604581D0/xx
Priority to PT97948102T priority patent/PT964697E/pt
Priority to PCT/SE1997/002094 priority patent/WO1998025645A1/en
Priority to DE69720065T priority patent/DE69720065T2/de
Priority to DK97948102T priority patent/DK0964697T3/da
Priority to EP97948102A priority patent/EP0964697B1/en
Priority to JP52656398A priority patent/JP2001517208A/ja
Priority to US09/319,736 priority patent/US20030087846A1/en
Priority to AT97948102T priority patent/ATE234628T1/de
Priority to CA002274837A priority patent/CA2274837A1/en
Priority to ES97948102T priority patent/ES2193408T3/es
Priority to AU54238/98A priority patent/AU5423898A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE9604581A 1996-12-12 1996-12-12 An agent against cancer and virus infections SE9604581D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9604581A SE9604581D0 (sv) 1996-12-12 1996-12-12 An agent against cancer and virus infections
AU54238/98A AU5423898A (en) 1996-12-12 1997-12-12 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
DK97948102T DK0964697T3 (da) 1996-12-12 1997-12-12 Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen
PCT/SE1997/002094 WO1998025645A1 (en) 1996-12-12 1997-12-12 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
DE69720065T DE69720065T2 (de) 1996-12-12 1997-12-12 Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
PT97948102T PT964697E (pt) 1996-12-12 1997-12-12 Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1
EP97948102A EP0964697B1 (en) 1996-12-12 1997-12-12 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
JP52656398A JP2001517208A (ja) 1996-12-12 1997-12-12 損傷した細胞ペプチドプロセッシングに関連する、例えばｂ７−１遺伝子で形質転換したｒｍａ−ｓ細胞上に発現される抗原またはエピトープの治療的応用
US09/319,736 US20030087846A1 (en) 1996-12-12 1997-12-12 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
AT97948102T ATE234628T1 (de) 1996-12-12 1997-12-12 Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
CA002274837A CA2274837A1 (en) 1996-12-12 1997-12-12 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
ES97948102T ES2193408T3 (es) 1996-12-12 1997-12-12 Aplicaciones terapeuticas de antigenos o epitopos asociados con un procesamiento celular insuficiente de peptidos, por ejemplo, expresados en celulas rma-s transfectadas con un gen b7-1.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604581A SE9604581D0 (sv) 1996-12-12 1996-12-12 An agent against cancer and virus infections

Publications (1)

Publication Number Publication Date
SE9604581D0 true SE9604581D0 (sv) 1996-12-12

Family

ID=20404956

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604581A SE9604581D0 (sv) 1996-12-12 1996-12-12 An agent against cancer and virus infections

Country Status (12)

Country Link
US (1) US20030087846A1 (da)
EP (1) EP0964697B1 (da)
JP (1) JP2001517208A (da)
AT (1) ATE234628T1 (da)
AU (1) AU5423898A (da)
CA (1) CA2274837A1 (da)
DE (1) DE69720065T2 (da)
DK (1) DK0964697T3 (da)
ES (1) ES2193408T3 (da)
PT (1) PT964697E (da)
SE (1) SE9604581D0 (da)
WO (1) WO1998025645A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524601A (ja) * 2000-09-15 2005-08-18 ザ スクリップス リサーチ インスティテュート 抗体による過酸化水素およびスーパーオキシド生成に関する方法および組成物
EP1994406A1 (en) * 2006-03-16 2008-11-26 Leiden University Medical Center Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
EP2089513A1 (en) * 2006-12-07 2009-08-19 Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2009008713A1 (en) * 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Tap-inhibitors from old world primate 1-herpesviruses and their use
FR2931485B1 (fr) * 2008-05-23 2011-06-17 Centre Nat Rech Scient Vaccin antitumoral comprenant des cellules tumorales modifiees
WO2012089225A1 (en) * 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
CN115023268A (zh) * 2020-01-29 2022-09-06 迈阿密大学 针对被病原体感染的细胞中诱导的抗原的疫苗接种
CN111979243B (zh) * 2020-08-24 2023-05-23 大连大学 利用CRISPR/Cas9系统构建TAP基因缺失的猪T2细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2024458A1 (en) * 1970-05-20 1971-12-02 Hartmann geb. Ungewitter, Philippine, Dr., 8000 München Tumour antigen - modified and potentiated by irradiation
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
CA2107537C (en) * 1992-10-02 2007-01-30 Lieping Chen Inhibition of tumor cell growth by administration of b7-transfected cells
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
WO1996009380A1 (en) * 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
CA2230195A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells

Also Published As

Publication number Publication date
DE69720065T2 (de) 2003-12-04
PT964697E (pt) 2003-07-31
ES2193408T3 (es) 2003-11-01
ATE234628T1 (de) 2003-04-15
WO1998025645A1 (en) 1998-06-18
EP0964697B1 (en) 2003-03-19
AU5423898A (en) 1998-07-03
JP2001517208A (ja) 2001-10-02
US20030087846A1 (en) 2003-05-08
DK0964697T3 (da) 2003-04-22
DE69720065D1 (de) 2003-04-24
CA2274837A1 (en) 1998-06-18
EP0964697A1 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
NZ319377A (en) polypeptides comprising a portion of a soluble M tuberculosis antigen
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
DK0527760T3 (da) Fremgangsmåder og præparater til vaccination mod HIV
SE9604581D0 (sv) An agent against cancer and virus infections
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
ATE229978T1 (de) Helicobacter proteine und impstoffe
ATE306939T1 (de) Mehrstufiger kaskade-erhöhungsimpfstoff
DK0724432T3 (da) Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
IS5329A (is) Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
ATE477275T1 (de) Antikörper gegen cd28
GEP20105118B (en) Anti-vegf antibodies
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
NO20005672L (no) Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GR3030834T3 (en) Herpes simplex virus vp16 vaccines
HUP9901958A2 (hu) Sertés reproduktív és respirációs szindróma vakcina
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
FI20070041L (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin